FDA Announcements we were waiting on:
CelGro Nerve
Q4 2020 US FDA 510K study commences
CelGro Tendon
Q4 2020 FDA pre-submission meeting
CelGro Dental
Q2 2021 FDA Approval (estimate)
Take your pick. An early approval for Dental being the best, a knock back being the worst in my range of expectations. Its a sad indictment of bio-tech management that I have seen in the last few years that I am leaning towards bad news, despite trying to remain rational. Just been roasted that many times by companies with great products and poor management.
Ann: Pause in Trading, page-16
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
66.0¢ |
Change
-0.050(7.04%) |
Mkt cap ! $139.0M | |||
| Open | High | Low | Value | Volume |
| 69.0¢ | 69.0¢ | 65.0¢ | $673.7K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5561 | 66.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 67.5¢ | 5270 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |